EUCLID Secondary Manuscripts

This is a randomized, double-blind, parallel group, multicenter phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke.

Awarded By

  • AstraZeneca AB

Contributors

Amount

  • $2,426,062.00

Start/End

  • 2016 - 2020